Business
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
ZUG, Switzerland, February 25, 2026--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3
About this update from Galderma Group Ag
[{"type":"image","alt":"Restylane syringe NASHA","displaySize":"","headline":null,"caption":"Restylane syringe NASHA","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/business-wire.com/8b4dbf7cbe7e645562ab2705a8ef805e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0U8hw9Sge83hBczF8LW.Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8b4dbf7cbe7e645562ab2705a8ef805e","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_X_3J46WWPvUEzUmlD1RvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8b4dbf7cbe7e645562ab2705a8ef805e","width":1200,"height":675}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/897642eeb7d097c921ca4b61628d57ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eWsLDipITu0s2wLF6HZbDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/897642eeb7d097c921ca4b61628d57ad","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Qsu_h5yhLtyRXOKD2sNhHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/897642eeb7d097c921ca4b61628d57ad","width":823,"height":209}}},{"type":"list","items":[{"val":[{"type":"text","content":"Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane® syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3","length":259,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7","length":272,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sust...